• Danaher Corporation has released its full-year 2025 results, reporting sales of US$24.57 billion versus US$23.88 billion a year earlier, while net income eased to US$3.61 billion from US$3.90 billion and diluted earnings per share from continuing operations slipped to US$5.03 from US$5.29.
• The combination of higher sales but lower earnings suggests rising costs or mix pressures across Danaher’s portfolio at a time when investors had been focused on contributions from its Diagnostics, Life Sciences, and Biotechnology businesses.
• We’ll now examine how Danaher’s revenue growth alongside weaker earnings shapes its investment narrative for long-term, fundamentals-focused investors.

AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Danaher's Investment Narrative?

For Danaher, the core investment case still comes down to believing in its position across Diagnostics, Life Sciences and Biotechnology, and in management’s ability to translate that into resilient cash flows over time. The latest 2025 results complicate that picture a bit: sales edged up to US$24.57 billion, but net income and EPS slipped, highlighting margin pressure just as investors had been hoping for cleaner earnings momentum. In the near term, that soft profitability may blunt enthusiasm around previously flagged catalysts such as the new share buyback program and ongoing portfolio investments, especially given Danaher’s premium valuation multiples and recent underperformance versus the broader market. At the same time, the share price reaction has been relatively contained so far, suggesting the market may see this more as a manageable bump than a reset of the long-term story.

However, one risk that stands out from here is what happens if those margins keep tightening. Danaher's shares have been on the rise but are still potentially undervalued by 14%. Find out what it's worth.

Exploring Other Perspectives

Eleven fair value estimates from the Simply Wall St Community span roughly US$142 to US$273, underscoring how differently investors view Danaher. Against that backdrop, the latest revenue growth but weaker earnings profile could be a key factor shaping which side of that wide range ultimately looks more realistic, especially if cost pressures persist or ease.

Explore 11 other fair value estimates on Danaher - why the stock might be worth 40% less than the current price!

Build Your Own Danaher Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Danaher research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Danaher research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Danaher's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Rare earth metals are the new gold rush. Find out which 34 stocks are leading the charge.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.